Randomized trial investigating the safety and efficacy of influenza vaccination in patients with antineutrophil cytoplasmic antibody‐associated vasculitis

Jeffs, Lisa; Peh, Chen Au; Jose, Matthew; Lange, Kylie; Hurtado, Plinio R

doi:10.1111/nep.12416

Cited by 32 publications

(27 citation statements)

References 28 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It should be noted that influenza vaccination does not appear to be associated with relapse in patients with AAV 136 137. In addition patients with GPA show an adequate immune response to influenza vaccination 138.…”

Section: Statementsmentioning

confidence: 97%

EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis

et al. 2016

View full text Add to dashboard Cite

In this article, the 2009 European League Against Rheumatism (EULAR) recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) have been updated. The 2009 recommendations were on the management of primary small and medium vessel vasculitis. The 2015 update has been developed by an international task force representing EULAR, the European Renal Association and the European Vasculitis Society (EUVAS). The recommendations are based upon evidence from systematic literature reviews, as well as expert opinion where appropriate. The evidence presented was discussed and summarised by the experts in the course of a consensus-finding and voting process. Levels of evidence and grades of recommendations were derived and levels of agreement (strengths of recommendations) determined. In addition to the voting by the task force members, the relevance of the recommendations was assessed by an online voting survey among members of EUVAS. Fifteen recommendations were developed, covering general aspects, such as attaining remission and the need for shared decision making between clinicians and patients. More specific items relate to starting immunosuppressive therapy in combination with glucocorticoids to induce remission, followed by a period of remission maintenance; for remission induction in lifethreatening or organ-threatening AAV, cyclophosphamide and rituximab are considered to have similar efficacy; plasma exchange which is recommended, where licensed, in the setting of rapidly progressive renal failure or severe diffuse pulmonary haemorrhage. These recommendations are intended for use by healthcare professionals, doctors in specialist training, medical students, pharmaceutical industries and drug regulatory organisations.

show abstract

Section: Statementsmentioning

confidence: 97%

EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Likewise, in other AIIRD, including patients with spondyloarthropathies, antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis and primary systemic sclerosis (pSS), adequate serological responses to influenza vaccination were found 30–32 48–53…”

Section: Resultsmentioning

confidence: 99%

“…Influenza vaccination did not influence activity of the underlying AIIRD in patients with RA,7 8 12 14 15 38 39 42 54 55 57 71–73 SLE,6 19 21 26 28 37 43 45–47 ANCA-associated vasculitis30 31 48 or systemic sclerosis 32 49. Adverse events of influenza vaccination in patients with AIIRD were comparable to those in HCs in most studies,7 19 21 23 30 59 65 including a meta-analysis in patients with SLE,46 In contrast, a meta-analysis including 13 studies in patients with RA concluded that local, mild adverse events occurred significantly more frequently in patients with RA 42…”

Section: Resultsmentioning

confidence: 99%

Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations

et al. 2019

View full text Add to dashboard Cite

AimTo present a systematic literature review (SLR) on efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD), aiming to provide a basis for updating the EULAR evidence-based recommendations.MethodsAn SLR was performed according to the standard operating procedures for EULAR-endorsed recommendations. Outcome was determined by efficacy, immunogenicity and safety of vaccination in adult patients with AIIRD, including those receiving immunomodulating therapy. Furthermore, a search was performed on the effect of vaccinating household members of patients with AIIRD on the occurrence of vaccine-preventable infections in patients and their household members (including newborns). The literature search was performed using Medline, Embase and the Cochrane Library (October 2009 to August 2018).ResultsWhile most investigated vaccines were efficacious and/or immunogenic in patients with AIIRD, some were less efficacious than in healthy control subjects, and/or in patients receiving immunosuppressive agents. Adverse events of vaccination were generally mild and the rates were comparable to those in healthy persons. Vaccination did not seem to lead to an increase in activity of the underlying AIIRD, but insufficient power of most studies precluded arriving at definite conclusions. The number of studies investigating clinical efficacy of vaccination is still limited. No studies on the effect of vaccinating household members of patients with AIIRD were retrieved.ConclusionEvidence on efficacy, immunogenicity and safety of vaccination in patients with AIIRD was systematically reviewed to provide a basis for updated recommendations.

show abstract

“…Several clinical trials have investigated the relapse rate of AAV after influenza vaccination. Overall, influenza vaccination does not seem to increase the relapse rate in patients with pre-existent AAV in remission [ 29 , 30 ]. Furthermore, the disease free survival was lower in patients not vaccinated [ 30 ].…”

Section: Discussionmentioning

confidence: 99%

MPO-ANCA associated vasculitis with mononeuritis multiplex following influenza vaccination

Eindhoven

Levels

Huisman

et al. 2017

Allergy Asthma Clin Immunol

View full text Add to dashboard Cite

BackgroundAlthough influenza vaccines are generally safe and effective, a variety of autoimmune phenomena have been reported after vaccination over the past years, such as Guillain–Barre syndrome, rheumatoid arthritis, pemphigus vulgaris, psoriasis, giant cell arteritis and anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV).Case reportWe describe the case of a 67-year old man who presented with a myeloperoxidase-ANCA associated vasculitis with renal involvement and mononeuritis multiplex after seasonal influenza vaccination. He was initially treated with intravenous cyclophosphamide and high-dose prednisolone followed by maintenance treatment consisting of azathioprine and prednisolone.ConclusionWe hypothesize that seasonal influenza vaccination triggered a systemic immune response in a susceptible patient to develop AAV with renal involvement and vasculitic neuropathy. In general, seasonal influenza vaccinations are considered to be safe, however, clinicians should be aware of this rare phenomenon.

show abstract

Randomized trial investigating the safety and efficacy of influenza vaccination in patients with antineutrophil cytoplasmic antibody‐associated vasculitis

Abstract: This study shows that the administration of influenza vaccine to patients in remission with anti-neutrophil cytoplasmic antibody-associated vasculitis is both safe and modestly efficacious.

Cited by 32 publications

References 28 publications

EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis

EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis

Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations

MPO-ANCA associated vasculitis with mononeuritis multiplex following influenza vaccination

Contact Info

Product

Resources

About